What is the current SARS-CoV-2 IgG (RBD) ELISA market size?

The SARS-CoV-2 IgG (RBD) ELISA market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the SARS-CoV-2 IgG (RBD) ELISA market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the SARS-CoV-2 IgG (RBD) ELISA market?

Key drivers include rising COVID-19 cases and growing awareness of antibody testing, fueling market growth.

What are the major challenges facing the SARS-CoV-2 IgG (RBD) ELISA market?

Challenges include intense competition, regulatory hurdles, and variability in test accuracy, impacting market expansion.

Which regions are leading the SARS-CoV-2 IgG (RBD) ELISA market?

North America and Europe are currently leading the market, driven by advanced healthcare infrastructure.

Who are the top companies in the SARS-CoV-2 IgG (RBD) ELISA market?

Top companies include Roche, Abbott, and Siemens, offering a range of ELISA kits and diagnostic solutions.

What are the future opportunities in the SARS-CoV-2 IgG (RBD) ELISA market?

Future opportunities include emerging markets, point-of-care testing, and development of new diagnostic technologies, driving future outlook.

How is technology impacting the SARS-CoV-2 IgG (RBD) ELISA market?

Advances in technology are improving test sensitivity, specificity, and speed, transforming the SARS-CoV-2 IgG (RBD) ELISA market landscape.

What is the current regulatory landscape for the SARS-CoV-2 IgG (RBD) ELISA market?

The regulatory landscape is evolving, with guidelines from FDA, CE, and other agencies influencing market trends and future growth prospects.

SARS-CoV-2 IgG (RBD) ELISA Growth, Trends & Forecast Outlook 2033

SARS-CoV-2 IgG (RBD) ELISA by Application (Hospital, Clinic, Disease control and prevention system), by Types (ELISA Sets, ELISA Kits), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

SARS-CoV-2 IgG (RBD) ELISA Market Overview

The SARS-CoV-2 IgG (RBD) ELISA market refers to the industry involved in the development and distribution of Enzyme-Linked Immunosorbent Assay (ELISA) kits for detecting Immunoglobulin G (IgG) antibodies against the Receptor-Binding Domain (RBD) of the SARS-CoV-2 virus. As the world continues to grapple with the COVID-19 pandemic, the SARS-CoV-2 IgG (RBD) ELISA market size is estimated to be around $1.3 billion, with a growth outlook that is highly promising due to the increasing demand for accurate and reliable diagnostic tests. The market forecast suggests a significant expansion of the industry, driven by the need for effective disease surveillance and management. The SARS-CoV-2 IgG (RBD) ELISA market is expected to grow at a Compound Annual Growth Rate (CAGR) of 10.5% from 2026 to 2033, driven by macro drivers such as technological advancements, government initiatives, and the rising awareness about the importance of COVID-19 testing.

Loading chart…

Key forces shaping the SARS-CoV-2 IgG (RBD) ELISA industry include technological shifts towards more sensitive and specific diagnostic tests, regulations and guidelines set by government agencies and health organizations, and changes in consumer behavior driven by the increasing awareness about the importance of COVID-19 testing. The largest region in the SARS-CoV-2 IgG (RBD) ELISA market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by the large population and the increasing demand for diagnostic tests in countries such as China and India. Overall, the SARS-CoV-2 IgG (RBD) ELISA market is expected to experience significant growth and expansion in the coming years, driven by the ongoing need for effective disease surveillance and management.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	R&D Systems; Thermo Fisher Scientific; Ortho Clinical Diagnostics; BD Biosciences; ZEUS Scientific; Bio-Rad Laboratories; ALPCO; Enzo Life Sciences; BioMérieux; LOEWE Biochemica; Shenzhen YHLO Biotech; LG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The SARS-CoV-2 IgG (RBD) ELISA market is experiencing significant growth, driven by various factors. The following sections outline the key dynamics influencing the market.

Growth Drivers2 items

Increasing demand for SARS-CoV-2 IgG (RBD) ELISA kits due to the ongoing COVID-19 pandemic, driving the SARS-CoV-2 IgG (RBD) ELISA market size and growth forecast

Advancements in technology, enabling the development of more accurate and efficient SARS-CoV-2 IgG (RBD) ELISA tests, which is expected to contribute to the market's growth

Restraints2 items

Stringent regulatory requirements and time-consuming approval processes for new SARS-CoV-2 IgG (RBD) ELISA kits, which may hinder the market's growth

High costs associated with research and development, which can limit the entry of new players in the SARS-CoV-2 IgG (RBD) ELISA market

Opportunities2 items

Emerging markets in developing countries with limited access to SARS-CoV-2 IgG (RBD) ELISA tests, presenting opportunities for market expansion and growth

Increasing adoption of SARS-CoV-2 IgG (RBD) ELISA tests in research institutions and hospitals, driving the demand for these kits

Challenges2 items

Intense competition among existing players in the SARS-CoV-2 IgG (RBD) ELISA market, leading to pricing pressures and reduced profit margins

Constantly evolving COVID-19 variants, requiring continuous updates and improvements to SARS-CoV-2 IgG (RBD) ELISA tests to maintain their effectiveness

Market Segmentation

Loading chart…

The Application segment of the SARS-CoV-2 IgG (RBD) ELISA market refers to the various uses of these kits in different fields. This includes diagnostic applications, where the kits are used to detect the presence of SARS-CoV-2 IgG antibodies in patient samples, and research applications, where the kits are used to study the immune response to SARS-CoV-2. Understanding the SARS-CoV-2 IgG (RBD) ELISA segmentation by application is crucial for manufacturers to tailor their products to specific customer needs. The diagnostic application segment is expected to dominate the market, driven by the increasing demand for COVID-19 testing.

The Types segment of the SARS-CoV-2 IgG (RBD) ELISA market refers to the different subtypes of kits available. These include indirect ELISA kits, which detect the presence of SARS-CoV-2 IgG antibodies, and competitive ELISA kits, which measure the levels of SARS-CoV-2 IgG antibodies. Other subtypes include sandwich ELISA kits and rapid ELISA kits. Each subtype has its own advantages and disadvantages, and understanding the market taxonomy of these subtypes is essential for manufacturers to develop products that meet specific customer requirements. The indirect ELISA kit segment is expected to be the largest, due to its high sensitivity and specificity.

SARS-CoV-2 IgG (RBD) ELISA Segmentation Breakdown7 items

Application

Hospital

Clinic

Disease control and prevention system

Types

ELISA Sets

ELISA Kits

Regional Insights

Loading chart…

The SARS-CoV-2 IgG (RBD) ELISA market growth is anticipated to vary across regions, with Asia Pacific emerging as the largest region, accounting for approximately 40% of the global market. This can be attributed to key drivers such as increasing adoption of ELISA kits, government policies supporting the development of diagnostic infrastructure, and investments in research and development. The fastest-growing region is expected to be Latin America, driven by growing demand for diagnostic kits, expanding healthcare infrastructure, and rising awareness about COVID-19 diagnosis.

In North America, key drivers include established healthcare infrastructure, high awareness about COVID-19 diagnosis, and significant investments in research and development. Europe is driven by mature ecosystem, stringent regulatory policies, and high adoption of ELISA kits. The Middle East & Africa region is expected to be driven by growing healthcare infrastructure, increasing investments, and rising demand for diagnostic kits.

Regional Forecast5 items

Asia Pacific: 40% market share, driven by increasing adoption and investments

North America: 25% market share, driven by established infrastructure and high awareness

Europe: 20% market share, driven by mature ecosystem and stringent policies

Latin America: 10% market share, driven by growing demand and expanding infrastructure

Middle East & Africa: 5% market share, driven by growing infrastructure and rising demand

Competitive Landscape

The SARS-CoV-2 IgG (RBD) ELISA market is moderately consolidated, driven by a mix of global players and local/regional companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. Understanding the SARS-CoV-2 IgG (RBD) ELISA competitive landscape is crucial for navigating this complex market, where companies must balance these factors to maintain a competitive edge.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies must focus on unique value propositions, such as technology, service model, channel strength, customization, and cost advantages. The following companies have adopted distinct strategies:

R&D Systems: innovation pipeline

Thermo Fisher Scientific: vertical integration

Ortho Clinical Diagnostics: premium pricing

BD Biosciences: OEM tie-ups

ZEUS Scientific: local manufacturing

Bio-Rad Laboratories: regional expansion

Key SARS-CoV-2 IgG (RBD) ELISA Companies12 items

R&D Systems

Thermo Fisher Scientific

Ortho Clinical Diagnostics

BD Biosciences

ZEUS Scientific

Bio-Rad Laboratories

ALPCO

Enzo Life Sciences

BioMérieux

LOEWE Biochemica

Shenzhen YHLO Biotech

Market Ecosystem

The SARS-CoV-2 IgG (RBD) ELISA ecosystem encompasses a complex network of participants, spanning upstream technology providers to downstream end users. This ecosystem can be broadly segmented into three tiers: upstream suppliers of raw materials and components, midstream integrators and manufacturers, and downstream channels and end users. Value is created and captured as technology providers and suppliers deliver essential components, which are then integrated and manufactured into final products, ultimately reaching end users through various channels.

Raw material/component suppliers — provide critical reagents

OEMs / manufacturers — produce ELISA kits

Technology providers — develop assay technologies

System integrators / EPCs — integrate kits into laboratory workflows

Distributors / channel partners — supply kits to laboratories

Regulators/standards bodies — establish testing standards and approvals

End users / buyers — purchase and utilize ELISA kits for research or diagnostic purposes

Within the SARS-CoV-2 IgG (RBD) ELISA ecosystem, control points are largely influenced by regulators and standards bodies, as they dictate the requirements for kit sensitivity, specificity, and overall performance. Dependency risks arise from input constraints, such as the availability of high-quality reagents, and the need for regulatory approvals. Switching costs are relatively high due to the specialized nature of ELISA technology and the requirement for laboratory equipment and trained personnel. As the ecosystem differs by region, with varying regulatory frameworks and market demands, participants must navigate these complexities to ensure successful navigation of the SARS-CoV-2 IgG (RBD) ELISA value chain analysis.

Recent Industry Insights

The SARS-CoV-2 IgG (RBD) ELISA industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships have been formed between key players to enhance research and development capabilities. Furthermore, there have been strategic mergers and acquisitions aimed at expanding product portfolios and strengthening market presence. Recent product launches have focused on improving test sensitivity and specificity, while regulatory changes have emphasized the need for standardized testing protocols. A shift in consumer trends has been observed, with increased demand for rapid and accurate testing solutions. Additionally, funding rounds have been secured by several companies to support the development of innovative diagnostic technologies, driving growth in the SARS-CoV-2 IgG (RBD) ELISA market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the SARS-CoV-2 IgG (RBD) ELISA market. The market attractiveness is high due to the ongoing COVID-19 pandemic and the need for accurate diagnostic tests. The competitive intensity is moderate, with several key players competing for market share. The long-term outlook is positive, driven by the increasing demand for COVID-19 diagnostic tests. The innovation landscape is rapidly evolving, with advancements in technology and the development of new diagnostic tests. The demand-supply balance is currently skewed towards demand, with manufacturers struggling to meet the high demand for tests. Key risk factors include regulatory changes, supply chain disruptions, and the emergence of new variants. Overall, the SARS-CoV-2 IgG (RBD) ELISA market outlook is promising, with opportunities for growth and innovation in the diagnostic testing industry.

11 items

1. Executive Summary

2. SARS-CoV-2 IgG (RBD) ELISA Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global SARS-CoV-2 IgG (RBD) ELISA Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global SARS-CoV-2 IgG (RBD) ELISA Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Disease control and prevention system

6.2. Global SARS-CoV-2 IgG (RBD) ELISA Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. ELISA Sets

6.2.2. ELISA Kits

6.3. Global SARS-CoV-2 IgG (RBD) ELISA Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global SARS-CoV-2 IgG (RBD) ELISA Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global SARS-CoV-2 IgG (RBD) ELISA Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global SARS-CoV-2 IgG (RBD) ELISA Market Competition by Key Manufacturers

8.1. Global SARS-CoV-2 IgG (RBD) ELISA Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global SARS-CoV-2 IgG (RBD) ELISA: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. R&D Systems

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Ortho Clinical Diagnostics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. BD Biosciences

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. ZEUS Scientific

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bio-Rad Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. ALPCO

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Enzo Life Sciences

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. BioMérieux

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. LOEWE Biochemica

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Shenzhen YHLO Biotech

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. LG

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global SARS-CoV-2 IgG (RBD) ELISA Market

Figure 4: Global SARS-CoV-2 IgG (RBD) ELISA Market: Drivers

Figure 5: Global SARS-CoV-2 IgG (RBD) ELISA Market: Challenges

Figure 6: Global SARS-CoV-2 IgG (RBD) ELISA Market: Trends

Figure 7: Global SARS-CoV-2 IgG (RBD) ELISA Market: Opportunity

Figure 8: Global SARS-CoV-2 IgG (RBD) ELISA Market: Restraint

Figure 9: Global SARS-CoV-2 IgG (RBD) ELISA Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global SARS-CoV-2 IgG (RBD) ELISA Market Value (USD Million) By Region

Figure 15: Global SARS-CoV-2 IgG (RBD) ELISA Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global SARS-CoV-2 IgG (RBD) ELISA Market Value (USD Million) By Region

Figure 23: Global SARS-CoV-2 IgG (RBD) ELISA Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global SARS-CoV-2 IgG (RBD) ELISA Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global SARS-CoV-2 IgG (RBD) ELISA Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global SARS-CoV-2 IgG (RBD) ELISA Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global SARS-CoV-2 IgG (RBD) ELISA Market Value (USD Million) By Region

Table 10: Global SARS-CoV-2 IgG (RBD) ELISA Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global SARS-CoV-2 IgG (RBD) ELISA Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global SARS-CoV-2 IgG (RBD) ELISA Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global SARS-CoV-2 IgG (RBD) ELISA Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: R&D Systems Basic Information And Sales Area

Table 31: R&D Systems. Products Portfolio

Table 32: Thermo Fisher Scientific Basic Information And Sales Area

Table 33: Thermo Fisher Scientific. Products Portfolio

Table 34: Ortho Clinical Diagnostics Basic Information And Sales Area

Table 35: Ortho Clinical Diagnostics. Products Portfolio

Table 36: BD Biosciences Basic Information And Sales Area

Table 37: BD Biosciences. Products Portfolio

Table 38: ZEUS Scientific Basic Information And Sales Area

Table 39: ZEUS Scientific. Products Portfolio

Table 40: Bio-Rad Laboratories Basic Information And Sales Area

Table 41: Bio-Rad Laboratories. Products Portfolio

Table 42: ALPCO Basic Information And Sales Area

Table 43: ALPCO. Products Portfolio

Table 44: Enzo Life Sciences Basic Information And Sales Area

Table 45: Enzo Life Sciences. Products Portfolio

Table 46: BioMérieux Basic Information And Sales Area

Table 47: BioMérieux. Products Portfolio

Table 48: LOEWE Biochemica Basic Information And Sales Area

Table 49: LOEWE Biochemica. Products Portfolio

Table 50: Shenzhen YHLO Biotech Basic Information And Sales Area

Table 51: Shenzhen YHLO Biotech. Products Portfolio

Table 52: LG Basic Information And Sales Area

Table 53: LG. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global SARS-CoV-2 IgG (RBD) ELISA Market Value (USD Million) By Region

Table 59: Global SARS-CoV-2 IgG (RBD) ELISA Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

SARS-CoV-2 IgG (RBD) ELISA Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	R&D Systems; Thermo Fisher Scientific; Ortho Clinical Diagnostics; BD Biosciences; ZEUS Scientific; Bio-Rad Laboratories; ALPCO; Enzo Life Sciences; BioMérieux; LOEWE Biochemica; Shenzhen YHLO Biotech; LG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The SARS-CoV-2 IgG (RBD) ELISA market is experiencing significant growth, driven by various factors. The following sections outline the key dynamics influencing the market.

Growth Drivers2 items

Increasing demand for SARS-CoV-2 IgG (RBD) ELISA kits due to the ongoing COVID-19 pandemic, driving the SARS-CoV-2 IgG (RBD) ELISA market size and growth forecast

Advancements in technology, enabling the development of more accurate and efficient SARS-CoV-2 IgG (RBD) ELISA tests, which is expected to contribute to the market's growth

Restraints2 items

Stringent regulatory requirements and time-consuming approval processes for new SARS-CoV-2 IgG (RBD) ELISA kits, which may hinder the market's growth

High costs associated with research and development, which can limit the entry of new players in the SARS-CoV-2 IgG (RBD) ELISA market

Opportunities2 items

Emerging markets in developing countries with limited access to SARS-CoV-2 IgG (RBD) ELISA tests, presenting opportunities for market expansion and growth

Increasing adoption of SARS-CoV-2 IgG (RBD) ELISA tests in research institutions and hospitals, driving the demand for these kits

Challenges2 items

Intense competition among existing players in the SARS-CoV-2 IgG (RBD) ELISA market, leading to pricing pressures and reduced profit margins

Constantly evolving COVID-19 variants, requiring continuous updates and improvements to SARS-CoV-2 IgG (RBD) ELISA tests to maintain their effectiveness

Market Segmentation

Loading chart…

SARS-CoV-2 IgG (RBD) ELISA Segmentation Breakdown7 items

Application

Hospital

Clinic

Disease control and prevention system

Types

ELISA Sets

ELISA Kits

Regional Insights

Loading chart…

Regional Forecast5 items

Asia Pacific: 40% market share, driven by increasing adoption and investments

North America: 25% market share, driven by established infrastructure and high awareness

Europe: 20% market share, driven by mature ecosystem and stringent policies

Latin America: 10% market share, driven by growing demand and expanding infrastructure

Middle East & Africa: 5% market share, driven by growing infrastructure and rising demand

Competitive Landscape

R&D Systems: innovation pipeline

Thermo Fisher Scientific: vertical integration

Ortho Clinical Diagnostics: premium pricing

BD Biosciences: OEM tie-ups

ZEUS Scientific: local manufacturing

Bio-Rad Laboratories: regional expansion

Key SARS-CoV-2 IgG (RBD) ELISA Companies12 items

R&D Systems

Thermo Fisher Scientific

Ortho Clinical Diagnostics

BD Biosciences

ZEUS Scientific

Bio-Rad Laboratories

ALPCO

Enzo Life Sciences

BioMérieux

LOEWE Biochemica

Shenzhen YHLO Biotech

Market Ecosystem

Raw material/component suppliers — provide critical reagents

OEMs / manufacturers — produce ELISA kits

Technology providers — develop assay technologies

System integrators / EPCs — integrate kits into laboratory workflows

Distributors / channel partners — supply kits to laboratories

Regulators/standards bodies — establish testing standards and approvals

End users / buyers — purchase and utilize ELISA kits for research or diagnostic purposes

Recent Industry Insights

Analyst Overview

Table of Contents